Notch3 enhances the synergistic effect of all-trans retinoic acid and calcipotriol in pancreatic stellate cell activation
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Targeting Notch3 with all-trans retinoic acid (ATRA) and calcipotriol shows promise for treating chronic pancreatitis (CP). This combination therapy effectively inhibits pancreatic stellate cell activation and fibrosis in CP models.
Area Of Science
- Gastroenterology and Hepatology
- Cell Biology
- Pharmacology
Background
- Chronic pancreatitis (CP) involves progressive fibrosis driven by activated pancreatic stellate cells (PSCs).
- Targeting activated PSCs is crucial for CP treatment, yet few methods exist.
- Notch3 receptor is highly expressed in activated PSCs, suggesting a role in PSC activation.
Purpose Of The Study
- To confirm the role of Notch3 in PSC activation.
- To investigate the effects of all-trans retinoic acid (ATRA) and calcipotriol on PSC activation and Notch3.
- To evaluate the therapeutic potential of targeting Notch3 in combination with ATRA and calcipotriol for CP.
Main Methods
- Notch3 was knocked down in PSCs to assess its impact on activation.
- PSCs were treated with ATRA and calcipotriol individually and in combination.
- In vitro and in vivo studies using a CP model were conducted to evaluate efficacy.
- Nuclear receptor inhibition was used to explore pathway interactions.
Main Results
- Notch3 plays a key role in PSC activation; ATRA and calcipotriol regulate Notch3 expression.
- ATRA and calcipotriol synergistically prevent and reverse PSC activation, an effect enhanced by Notch3 knockdown.
- Combination therapy targeting Notch3 with ATRA and calcipotriol demonstrated efficacy in a CP model.
- ATRA and calcipotriol do not act via RARβ or VDR but depend on Notch3 for PSC regulation.
Conclusions
- Notch3 is a viable therapeutic target for inhibiting PSC activation.
- ATRA and calcipotriol modulate Notch3 expression in PSCs.
- Combined targeting of Notch3 with ATRA and calcipotriol offers a promising novel strategy for managing pancreatic fibrosis in CP.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...